% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • kyle.ramer kyle.ramer Apr 30, 2013 10:31 AM Flag

    11th Vaccines Research & Development: All Things Considered Conference, to be held in Boston,

    Day 3 - Wednesday, July 10, 2013

    DNA & RNA Vaccines

    8:10 Synthetic Vaccines for Difficult Targets
    David Weiner, Professor, Department of Pathology and Laboratory Medicine; Chair, Gene Therapy and Vaccine Program, CAMB, University of Pennsylvania Perelman School of Medicine
    DNA vaccines represent an important vaccine technology, which has many conceptual advantages over traditional vaccine platforms. However, in humans the immune potency of this approach has been poor. We have developed a combination of technologies for plasmid optimization, adjuvant technology which when combined with enhanced EP delivery results in dramatically improved immune potency of this platform in primates and humans. These combined DNA approaches drive immune response similar or superior to live viral vector protocols in important model systems including HIV, HPV therapy, Influenza among others. We will present data in animal models and in human studies that illuminate specific features of these improved DNA vaccine and benchmark their development against other important vaccine technologies. These studies have critical implications for the treatment or prevention of infection by difficult pathogens and in the expanding theater of immune therapy.

    • New approaches to development of CTL in humans
    • Details of the Synthetic DNA platform
    • Novel Vaccine strategies for diverse pathogens
    • Clinical performance in immune therapy setting

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
10.61-0.08(-0.75%)May 27 4:00 PMEDT